drugset / Trial / NCT01678976

Tolerability and Pharmacokinetics of a Single 900 mg Oral Dose of BIA 2-093 and Oxcarbazepine in Healthy Volunteers

NCT01678976

Phase 1 Completed 13 enrolled Bial - Portela C S.A.
RandomizedCrossoverOpen-labelTreatment

Summary

To investigate the pharmacokinetics of a single 900 mg oral dose of BIA 2-093 and a single 900 mg oral dose of Oxcarbazepine in healthy volunteers and to assess the tolerability of a single 900 mg dose of BIA 2-093 and Oxcarbazepine.

Timeline

Start
2002-03
Primary completion
2002-04
Completion
2002-04

Drugs

EvaluationDrugModalityDoseRoute
Subject Eslicarbazepine acetate Unknown 900 mg Oral
Subject Oxcarbazepine Small molecule 900 mg Oral

Indications